Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine vs. Methohexital in ECT for Major Depressive Disorder
NCT02752724Completed
- Sponsor
- VA Puget Sound Health Care System
- Start
- Mar 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ketamine in major depressive disorder (MDD) and bipolar disorder (BD) (2 arms), sponsored by VA Puget Sound Health Care System. Primary endpoints: Patient Health Questionnaire 9 and Hamilton Depression Rating Scale. Started Mar 2016; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT02752724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02752724.